Korea's MBD prices KOSDAQ IPO at $10.4M, 27% below its range
What's the deal? South Korean precision-oncology firm MBD set its IPO price at US$5.87 per share, raising about US$11.7M (roughly $10.4 million) ahead of its KOSDAQ listing. The company is selling 2 million new shares, giving it an expected market value of around US$84.2M.
Why now? MBD wants the proceeds to scale up manufacturing of its automation equipment, fund research and development, and expand abroad. It builds 3D cell-culture automation tools around its ASFA platform, plus drug-efficacy testing (CRO) and the OncoSensi anti-cancer sensitivity service.
What's the endgame? The company is pushing a recurring-revenue model: it sells ASFA equipment, then supplies the dedicated consumables and software needed to run it. It is also using overseas partnerships and distribution networks to win global customers.
Dig deeper: Bookbuilding ran from November 2 to 6, drawing 925 institutions and a 187:1 subscription rate. Yet the final US$5.87 price landed 27.1% below the bottom of its US$8.05–US$9.81 indicated range, cutting the raise from a possible US$0.02–US$19.6M.
"We determined the final offer price by comprehensively considering the institutional demand results and market conditions," a representative of lead underwriter Hana SecuritiesDealroom has a profile for this one. Try Dealroom → said (translated from Korean).
Chief executive officer Koo Bo-sung called the listing "an important turning point" for expanding MBD's competitiveness in global markets.
What's next? MBD runs its retail subscription from November 12 to 13 before listing on KOSDAQ, with Hana Securities as lead manager.
The signal: A strong demand rate paired with a price well below range points to a cautious Korean biotech IPO market, where recent offerings have priced at or under their ranges and many KOSDAQ newcomers have struggled to hold their debut prices. The 187:1 reception is a qualified one — not proof of conviction in MBD's commercial prospects.
Read more: edaily.co.kr
Image credit: Generated with Gemini
